Gynecologic Oncology Unit, Azienda Ospedaliero-Universitaria Policlinico di Sant'Orsola, 40138 Bologna, Italy.
Centro di Studio e Ricerca delle Neoplasie Ginecologiche (CSR), University of Bologna, 40138 Bologna, Italy.
Int J Mol Sci. 2020 Sep 29;21(19):7188. doi: 10.3390/ijms21197188.
Since 2016, our hospital has applied tumor testing with immunohistochemistry (IHC) in endometrial cancer in order to detect mutations of mismatch repair genes (MMR). All cases with MMR deficiency proteins expression are sent for genetic testing, except those with protein deficiency, in which case genetic testing is performed if negative for promoter hypermethylation. The primary aim of this study was to investigate the ability of our algorithm to identify Lynch syndrome (LS). The Secondary aims were to investigate the relationship between MMR status and clinicopathological features and prognosis of primary endometrial cancer (EC). From January 2016 to December 2018, 239 patients with EC were retrospectively analyzed and subdivided according to MMR status. Patients were divided in three groups: MMR proficient, LS and Lynch-like cancer (LLC). LS was characterized by a lower age and BMI, more use of contraceptive and less use of hormonal replacement therapy, nulliparity and a trend versus a better prognosis. LLC appeared more related to MMR proficient than LS and exhibited a more aggressive behavior. Our multidisciplinary approach permitted a correct diagnosis of germline mutation in patients with newly diagnosis EC and it confirmed clinicopathologic and prognostic characteristics of LS.
自 2016 年以来,我院在子宫内膜癌中应用肿瘤免疫组织化学(IHC)检测错配修复基因(MMR)的突变。除了蛋白缺失的病例,如果启动子超甲基化检测为阴性,则会对 MMR 蛋白表达缺失的所有病例进行基因检测。本研究的主要目的是探讨我们的算法识别林奇综合征(LS)的能力。次要目的是探讨 MMR 状态与原发性子宫内膜癌(EC)的临床病理特征和预后的关系。回顾性分析 2016 年 1 月至 2018 年 12 月我院收治的 239 例 EC 患者,根据 MMR 状态进行分组。患者分为三组:MMR 正常、LS 和林奇样癌(LLC)。LS 患者的年龄和 BMI 较低,更多地使用避孕药,较少使用激素替代疗法,多为未婚,且预后较好。与 LS 相比,LLC 似乎与 MMR 正常更相关,表现出更具侵袭性的行为。我们的多学科方法允许对新诊断为 EC 的患者进行胚系突变的正确诊断,并证实了 LS 的临床病理和预后特征。